Alexza Pharmaceuticals Inc: (NASD: ALXA)

$4.68

0.23 (5.17%)

Volume 719,648

May 21 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		4.39 - 4.75
	
		52wk Low - High
		2.55 - 6.65
	
		Previous Close
		4.45
	
		Avg. Volume
		826,465
	
		Industry
		MED-DRUGS
	
		Market Cap
		69.82 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.74
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-2.65
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		NA
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		107 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of NA

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -2.65
                        
                            Current Quarter Estimate
                            -0.50
                        
                            Most Accurate Estimate
                            -0.50
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            08-07-2013
                        
                            EPS Last Year
                            -2.37
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Alexza Pharmaceuticals is an emerging pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The Company's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that allows rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience.   
Full ALXA Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ALXA Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.50	-0.46	-2.65	-0.90
Number of Estimates	1	1	1	1
Low Estimate	-0.50	-0.46	-2.65	-0.90
High Estimate	-0.50	-0.46	-2.65	NA
Year Ago EPS	-0.58	-0.52	-2.24	-2.65
EPS Growth	13.79%	11.54%	-18.30%	66.04%

More ALXA Estimates

Average Earnings Estimates for ALXA

EPS Growth for ALXA

Industry Analysis

Name	Symbol	Previous Close
ALEXZA PHARMACT	ALXA	4.45
JAZZ PHARMACEUT	JAZZ	58.49
SALIX PHARM-LTD	SLXP	58.75
SANTARUS INC	SNTS	22.10
USANA HLTH SCI	USNA	68.03
BIOCRYST PHARMA	BCRX	1.71
CATALYST PHARMA	CPRX	0.87
CELL THERAPEUT	CTIC	1.22
CUBIST PHARM	CBST	53.48
ELAN CP PLC ADR	ELN	12.04

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Teva - Alexza Sign Deal for Adasuve

May 13, 2013

Good News for Alexza Pharma

Aug 23, 2012

Zacks #1 Rank Additions for Friday

Jul 20, 2012

Zacks #1 Rank Additions for Wednesday

Jul 18, 2012

Zacks #1 Rank Additions for Monday

Jul 16, 2012

Zacks #1 Rank Additions for Tuesday

Jul 10, 2012

Zacks #1 Rank Additions for Thursday

Jul 05, 2012

Report Not Available

More ALXA Zacks Commentary

Financials

EPS TTM	-2.37
Sales	4
Net Income	-45
Price/Earnings	NA
Price/Book	NA
Price/Cash Flow	NA
Price/Sales	23.95

More ALXA Financials

News

Benzinga`s Top Pre-Market Losers - Benzinga

May 16, 2013

Teva and Alexza Announce Teva`s License to Market ADASUVE in the U.S. - Benzinga

May 8, 2013

Benzinga`s Top Upgrades - Benzinga

Apr 3, 2013

UPDATE: Piper Jaffray Upgrades Alexza Pharmaceuticals to Overweight on Adasuve Market Adoption - Benzinga

Apr 3, 2013

Alexza Pharma Shares Moving Higher as Co. Wins Marketing Authorization for ADASUVE in EU - Benzinga

Feb 21, 2013

MAP Investors: X Marks the Buyout - TheMotleyFool

Jan 23, 2013

This Diagnostic Company May Double in 2013 - TheMotleyFool

Jan 15, 2013

UPDATE: Piper Jaffray Initiates Coverage on Alexza Pharmaceuticals to Neutral Rating, $5 PT - Benzinga

Jan 4, 2013

See All News Stories on ALXA

Broker Recommendations

Current ABR	1.67
ABR (Last Week)	1.67
# of recs in ABR	3
Average Target Price	10.00
Industry Rank by ABR	107 out of 265
Rank in Industry	15 out of 91

More ALXA Broker Recommendations

Day Low - High	4.39 - 4.75
52wk Low - High	2.55 - 6.65
Previous Close	4.45
Avg. Volume	826,465
Industry	MED-DRUGS
Market Cap	69.82 M
Div - Yield	0.00 - 0.00
Beta	1.74
PE (Forward)	0.00
Current Year Est.	-2.65
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-2.65
Current Quarter Estimate	-0.50
Most Accurate Estimate	-0.50
Earnings ESP	0.00%
Next Earnings Report Date	08-07-2013
EPS Last Year	-2.37
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Alexza Pharmaceuticals Inc: (NASD: ALXA)

$4.68

0.23 (5.17%)

Volume 719,648

May 21 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description